<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">We kindly acknowledge NIH funding: R21TR001718 from NCATS and R44GM122196-02A1 from NIGMS (PI â€“ Sean Ekins). Dr. Mindy Davis is gratefully acknowledged for assistance with the NIAID virus screening capabilities, Task Order number B22. Dr. Luke Mercer and Caleb Goodin (Cambrex) are acknowledged for their work on lysosome accumulation assays. Dr. Vadim Makarov is kindly acknowledged for discussions on Russian antivirals. SE is founder and owner of Collaborations Pharmaceuticals, Inc. TRL is an employee of Collaborations Pharmaceuticals, Inc. Collaborations Pharmaceuticals, Inc. has an orphan designation on tilorone for use against Ebola and a provisional patent submitted for use for Marburg.</p>
